%0 Journal Article
%A Gudiol, Carlota
%A Royo-Cebrecos, Cristina
%A Abdala, Edson
%A Akova, Murat
%A Alvarez, Rocio
%A Maestro-de la Calle, Guillermo
%A Cano, Angela
%A Cervera, Carlos
%A Clemente, Wanessa T.
%A Martin-Davila, Pilar
%A Freifeld, Alison
%A Gomez, Lucia
%A Gottlieb, Thomas
%A Gurgui, Merce
%A Herrera, Fabian
%A Manzur, Adriana
%A Maschmeyer, Georg
%A Meije, Yolanda
%A Montejo, Miguel
%A Peghin, Maddalena
%A Rodriguez-Bano, Jesus
%A Ruiz-Camps, Isabel
%A Sukiennik, Teresa C.
%A Tebe, Cristian
%A Carratala, Jordi
%T Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia
%D 2017
%@ 0066-4804
%U http://hdl.handle.net/10668/18998
%X beta-Lactam/beta-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum beta-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.
%K ESBLs
%K Bloodstream infection
%K Neutropenia
%K Beta-lactam/beta-lactamase inhibitors
%K Mortality
%K Escherichia-coli
%~